by cognosadminteam | Nov 2, 2021 | News
2 NOVEMBER, 2021 Co-Founder and CIO Josh Shachar Discusses the Evolution of the Cognos Vision In a recent presentation to the Cognos Shareholders, Josh Shachar, the Co-Founder and Chief Innovation Officer for Cognos Therapeutics presented a compelling vision for the...
by cognosadminteam | Nov 1, 2021 | News
Cognos Therapeutics Corp. Engages Maxim Group LLC for Investment Banking and Financial Advisory Services Cognos Therapeutics has signed a Letter of Engagement to retain Maxim Group LLC (“Maxim”) to provide financial advisory and investment banking services, including...
by cognosadminteam | Oct 28, 2021 | News
28 OCTOBER, 2021 Cognos Announces Addition of New Clean Room To Expand Its Development Capabilities Cognos Therapeutics announced today the addition of an ISO-7 Clean Room to their existing Los Angeles laboratory facility (WATCH THE OVERVIEW VIDEO NOW). The clean...
by cognosadminteam | Feb 27, 2019 | News
27 FEBRUARY, 2019 Dr. Susan Alpert, MD, PhD, Joins Cognos Therapeutics as Lead Regulatory Consultant Dr. Susan Alpert, MD, PhD, has been named Lead Regulatory Consultant for Cognos Therapeutics, Inc. Dr. Alpert is considered one of the top U.S. regulatory experts....
by cognosadminteam | Jan 12, 2018 | News
11 JANUARY, 2018 Cognos’ SINNAIS Smart Implantable Pump has potential to Improve CAR T Cell Efficacy in Solid Tumors Cognos Therapeutics (Cognos Thx) is exploring the potential of using its SINNAIS implantable pump as the delivery mechanism for a new drug...
by cognosadminteam | Jul 13, 2017 | News
13 JULY, 2017 Cognos Therapeutics plans to conduct a twenty-patient human clinical trial using direct delivery of Herceptin (a Genentech drug) to prove drug safety in the brain region. Cognos Therapeutics (Cognos Thx) plans to use Herceptin, a Genentech drug, to be...
Recent Comments